tiprankstipranks
Trending News
More News >
Shanghai Pharmaceuticals Holding Co Class H (HK:2607)
:2607
Hong Kong Market

Shanghai Pharmaceuticals Holding Co (2607) Income Statement

Compare
4 Followers

Shanghai Pharmaceuticals Holding Co Income Statement

Last quarter (Q1 2025), Shanghai Pharmaceuticals Holding Co's total revenue was ¥70.76B, an increase of 0.87% from the same quarter last year. In Q1, Shanghai Pharmaceuticals Holding Co's net income was ¥1.33B. See Shanghai Pharmaceuticals Holding Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
¥ 275.25B¥ 260.30B¥ 231.98B¥ 215.82B¥ 191.91B
Gross Profit
¥ 30.63B¥ 30.93B¥ 30.49B¥ 28.54B¥ 27.44B
Operating Expenses
¥ 22.49B¥ 23.26B¥ 21.71B¥ 20.62B¥ 19.30B
Depreciation and Amortization
¥ 2.42B¥ 2.19B¥ 2.22B¥ 2.14B¥ 2.14B
EBITDA
¥ 12.06B¥ 10.90B¥ 12.44B¥ 10.55B¥ 10.44B
Operating Income
¥ 8.14B¥ 7.67B¥ 9.01B¥ 8.21B¥ 7.18B
Other Income/Expenses
¥ -120.71M¥ -612.94M¥ -206.30M¥ -61.67M¥ -8.91M
Pretax Income
¥ 8.02B¥ 7.05B¥ 8.81B¥ 8.14B¥ 7.18B
Net Income
¥ 4.55B¥ 3.77B¥ 5.62B¥ 5.09B¥ 4.50B
Per Share Metrics
Basic EPS
¥ 1.23¥ 1.02¥ 1.61¥ 1.79¥ 1.58
Diluted EPS
¥ 1.23¥ 1.02¥ 1.61¥ 1.79¥ 1.58
Weighted Average Shares Outstanding
3.70B 3.70B 3.48B 2.84B 2.84B
Weighted Average Shares Outstanding (Diluted)
3.70B 3.70B 3.49B 2.85B 2.85B
Currency in CNY

Shanghai Pharmaceuticals Holding Co Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis